Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Operating Expenses for 6 consecutive years, with $70.4 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 25.41% to $70.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $244.8 million through Dec 2025, up 30.27% year-over-year, with the annual reading at $244.8 million for FY2025, 30.27% up from the prior year.
  • Operating Expenses for Q4 2025 was $70.4 million at 4D Molecular Therapeutics, up from $61.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $70.4 million in Q4 2025, with the low at $18.3 million in Q1 2021.
  • Average Operating Expenses over 5 years is $38.4 million, with a median of $33.3 million recorded in 2023.
  • Peak annual rise in Operating Expenses hit 57.69% in 2021, while the deepest fall reached 8.92% in 2021.
  • Over 5 years, Operating Expenses stood at $24.9 million in 2021, then increased by 20.56% to $30.0 million in 2022, then grew by 22.24% to $36.6 million in 2023, then skyrocketed by 53.19% to $56.1 million in 2024, then rose by 25.41% to $70.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $70.4 million, $61.3 million, and $59.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.